[Federal Register Volume 84, Number 115 (Friday, June 14, 2019)]
[Notices]
[Pages 27791-27792]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-12527]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.


[[Page 27792]]


    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; SEP for NIDA Medications Development.
    Date: June 25, 2019.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: National Institutes of Health, Neuroscience Center 
Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852 
(Telephone Conference Call).
    Contact Person: Ivan K. Navarro, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Boulevard, Room 4242, MSC 9550, Bethesda, MD 20892, 
301-827-5833, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Laboratories for Early Clinical Evaluation of 
Pharmacotherapies for Substance Use Disorders (UG1) Clinical Trials 
Required.
    Date: June 25, 2019.
    Time: 11:30 a.m. to 4:00 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: National Institutes of Health, Neuroscience Center 
Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852 
(Telephone Conference Call).
    Contact Person: Ivan K. Navarro, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Boulevard, Room 4242, MSC 9550, Bethesda, MD 20892, 
301-827-5833, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: June 10, 2019.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-12527 Filed 6-13-19; 8:45 am]
 BILLING CODE 4140-01-P